Reforming off-label promotion to enhance orphan disease treatment

Science

Volumn 327, Issue 5963, 2010, Pages 273-274

  Liang, Bryan A ^a,b   Mackey, Tim ^a  

^a CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE TREATMENT; DRUG; HEALTH POLICY; ORPHAN; PUBLIC ACCESS;

CLINICAL ASSESSMENT; DEMENTIA; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MONITORING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROMOTION; HUMAN; MEDICAL EDUCATION; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RARE DISEASE; RISK MANAGEMENT; SHORT SURVEY; TREATMENT DURATION; ARTICLE; DRUG APPROVAL; DRUG LEGISLATION; LEGAL ASPECT; OFF LABEL DRUG USE; POSTMARKETING SURVEILLANCE; UNITED STATES;

DRUG APPROVAL; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; OFF-LABEL USE; ORPHAN DRUG PRODUCTION; PRODUCT SURVEILLANCE, POSTMARKETING; RARE DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74549213090     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1181567     Document Type: Short Survey

References (26)

1. U.S.C. 21 § 396 (2000).
2. B. M. Psaty, W. Ray, JAMA 299, 1949 (2008).
3. D. C. Radley, S. N. Finkelstein, R. S. Stafford, Arch. Intern. Med. 166, 1021 (2006).
4. R. S. Stafford, N, Engl. J. Med. 358, 1427 (2008).
5. S. Salbu, Fla. Law Rev. 51, 181 (1999).
6. M. G. Krammer, National Organization for Rare Disorders and the Experiences of the Rare Disorders Community (National Organization for Rare Disorders, Washington, DC, 2003).
7. National Institutes of Health (NIH), NIH launches undiagnosed diseases program, NIH News (NIH, Bethesda, MD, 2008); www.nih.gov/news/health/may2008/ nhgri-19.htm.
8. In Need of Diagnostics, Inc., http://inod.org/default.aspx.
9. A. Berenson, New York Times, 18 December 2006, p. A1.
10. J. Boos, Ann. Oncol. 14, 1(2003).
11. T. Hampton, JAMA 297, 683 (2007).
12. Rarer Cancers Forum, Off Limits: An Investigation into How NHS Organisations Determine Requests for the Use of Off-Label Treatments for Cancer Patients (Rarer Cancers Forum, Canterbury, UK, 2009); www.rarercancers. org.uk/news/current/off-limits-new-rarer-cances-forum-report/.
13. M. Schlander, M. Beck, Curr. Med. Res. Opin. 25, 1285 (2009).
14. G. J. Brewer, Transl. Res. 154, 314 (2009).
15. E. A. Richey et al., J. Clin. Oncol. 27, 4398 (2009).
16. Department of Human and Health Services (DHHS), The Orphan Drug Act: Implementation and Impact (OEI-0900-00380, DHHS, Washington, DC, 2001).
17. Canadian Organization for Rare Disorders, Canada's Orphan Drug Policy: Learning from the Best (Canadian Organization for Rare Disorders, Toronto, 2005).
18. A. Pollack, New York Times, 30 April 1990, p. D1.
19. Wash. Legal Found, v. Friedman, 13 F. Supp. 2d 51, 55 (D.D.C. 1998).
20. FDA, Fed. Regist. 61, 52800 (1996).
21. FDA, Fed. Regist. 62, 64073 (1997).
22. M. M. Mello, D. M. Studdert, T. A. Brennan, N. Engl. J. Med. 360, 1557 (2009).
23. FDA, Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices (FDA, Silver Spring, MD, 2009).
24. B. A. Liang, Harvard J. Legis. 44, 363 (2007).
25. FDA, FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease (FDA news release, FDA, Silver Spring, MD, 2008); www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116835.htm.
26. R. Abelson, A. Pollack, New York Times, 27 January 2009, p. A22.